Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 19 Researches
7.4
USERS' SCORE
Moderately Good
Based on 6 Reviews
7.9
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
Vitamin D (as cholecalciferol)
125 mcg
625%
Iodine [from Sea-Iodine™ Complex Blend (organic kelp and bladderwrack extracts, potassium iodide)]
1,000 mcg
667%
Top Medical Research Studies
9
Iodine treatment aids recurrent cancer
We observed a compelling case where a biodegradable hydrogel spacer was used alongside iodine-125 brachytherapy to treat recurrent prostate cancer. This innovative approach involved placing the spacer to create space between the prostate and the rectum, which significantly reduced radiation exposure to healthy tissues during the treatment.
Following initial external beam radiotherapy in 2015, the patient showed signs of local recurrence by 2022. To address this, the treatment plan included not just the iodine-125 brachytherapy but also the hydrogel spacer, which was placed in January 2024 just before the radiation treatment. Six months later, we noted a remarkable drop in the patient’s prostate-specific antigen (PSA) levels, indicating a positive response to the treatment.
This case showcases the potential benefits of using iodine treatment in combination with advanced techniques like hydrogel spacers. The results suggest that this method not only improves the effectiveness of therapy but also ensures higher safety by protecting adjacent tissues from unnecessary radiation damage. Overall, we find this integration of technology highly beneficial for managing recurrent cancer challenges.
Following initial external beam radiotherapy in 2015, the patient showed signs of local recurrence by 2022. To address this, the treatment plan included not just the iodine-125 brachytherapy but also the hydrogel spacer, which was placed in January 2024 just before the radiation treatment. Six months later, we noted a remarkable drop in the patient’s prostate-specific antigen (PSA) levels, indicating a positive response to the treatment.
This case showcases the potential benefits of using iodine treatment in combination with advanced techniques like hydrogel spacers. The results suggest that this method not only improves the effectiveness of therapy but also ensures higher safety by protecting adjacent tissues from unnecessary radiation damage. Overall, we find this integration of technology highly beneficial for managing recurrent cancer challenges.
Read More
4
We investigated how effective iodine treatment is for patients with differentiated thyroid cancer (DTC) that has spread to distant sites in the body. This cohort study included 128 patients who underwent iodine-131 radiotherapy, specifically comparing those whose cancer was resistant to this treatment versus those who responded well to it.
Our findings revealed that mutations in the telomerase reverse transcriptase (TERT) gene were associated with a poorer response to iodine therapy among patients with distant metastatic DTC. Among the 75 patients classified as resistant to treatment, we observed a higher likelihood of disease progression in older patients, specifically those aged 55 years and older.
Notably, we discovered that other factors, such as the size of the tumor and the presence of lymph node metastasis, also played a role in treatment outcomes. As we followed these RAIR patients, we found that while some managed to maintain control over their disease, others experienced significant progression.
Overall, our research highlights the complexities of iodine therapy in advanced thyroid cancer cases and emphasizes the need for personalized treatment strategies based on genetic and clinical indicators.
Our findings revealed that mutations in the telomerase reverse transcriptase (TERT) gene were associated with a poorer response to iodine therapy among patients with distant metastatic DTC. Among the 75 patients classified as resistant to treatment, we observed a higher likelihood of disease progression in older patients, specifically those aged 55 years and older.
Notably, we discovered that other factors, such as the size of the tumor and the presence of lymph node metastasis, also played a role in treatment outcomes. As we followed these RAIR patients, we found that while some managed to maintain control over their disease, others experienced significant progression.
Overall, our research highlights the complexities of iodine therapy in advanced thyroid cancer cases and emphasizes the need for personalized treatment strategies based on genetic and clinical indicators.
Read More
9
Iodine peptides show cancer treatment promise
We explored the effectiveness of iodine-labeled peptides, specifically I-TFMP-Y4 and I-Caerin 1.1, in treating hepatocellular carcinoma, a common type of liver cancer. Our study included in vitro experiments where we assessed how these peptides affected the growth of liver cancer cells, as well as in vivo tests using a hormone-treated nude mouse model.
We found that both I-Caerin 1.1 and I-TFMP-Y4 were effective at inhibiting the proliferation of Hepg2 cells, which are a model for liver cancer. Interestingly, while I-Caerin 1.1 showed a significant impact, we observed that TFMP-Y4 alone did not inhibit the liver cancer cells, suggesting its effectiveness might rely on its pairing with Iodine.
Additionally, we noted that I-TFMP-Y4 has the potential to lessen adverse reactions during treatment compared to I-Caerin 1.1. This finding is particularly important as it may improve the safety profile of the treatment, making it more acceptable for patients undergoing therapy.
We found that both I-Caerin 1.1 and I-TFMP-Y4 were effective at inhibiting the proliferation of Hepg2 cells, which are a model for liver cancer. Interestingly, while I-Caerin 1.1 showed a significant impact, we observed that TFMP-Y4 alone did not inhibit the liver cancer cells, suggesting its effectiveness might rely on its pairing with Iodine.
Additionally, we noted that I-TFMP-Y4 has the potential to lessen adverse reactions during treatment compared to I-Caerin 1.1. This finding is particularly important as it may improve the safety profile of the treatment, making it more acceptable for patients undergoing therapy.
Read More
Most Useful Reviews
7.5
Aids bone health
I take vitamin D3 constantly; it ensures normal growth and development of bones, preventing rickets and osteoporosis. It regulates mineral metabolism, promotes muscle tone, improves immunity, and is vital for thyroid function and blood clotting. It also helps restore protective sheaths around nerves and regulates blood pressure and heartbeat while inhibiting cancer cell growth. Good company and optimal dosage for winter. You can take it every other day if necessary.
Read More
7.5
Value price
Great combo! This product tests well and has become a staple for us, primarily for the D3 and also for the good amount of natural iodine, essential for metabolism and anti-cancer. Great price, too, and it comes in a blue bottle for an added bonus. We trust this.
Read More
7
Essential for health
Fine! Research data from recent years indicate a pandemic of vitamin D deficiency, and this vitamin is everything! Normal levels of vitamin D protect against cancer, diabetes, depression, etc. It facilitates phosphorus and calcium absorption and acts as an immunomodulator. Its deficiency frequently leads to viral and bacterial infections.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 19 Researches
7.4
- All Researches
9
We explored the potential of vitamin D-based micelles designed to deliver paclitaxel, a key chemotherapy drug, specifically for pancreatic cancer treatment. This study focuses on developing enzyme-responsive micelles that not only carry paclitaxel but also utilize vitamin D as an integral part of the delivery system.
The micelles are made by combining vitamin D with polyethylene glycol, resulting in tiny structures that can release their drug load when interacting with enzymes typically found in pancreatic cancer cells. We observed that these micelles showed promising results in laboratory settings, enhancing the effectiveness of paclitaxel against aggressive pancreatic cancer cells compared to using paclitaxel alone.
Moreover, we noted that the vitamin D in the micelles may play a dual role: serving as both a hydrophobic core for drug delivery and a contributor to synergetic therapeutic effects. Our findings suggest that leveraging vitamin D in this way could increase the efficacy of existing treatment options for pancreatic cancer patients, which is particularly significant given the challenges currently faced in treating this disease.
The micelles are made by combining vitamin D with polyethylene glycol, resulting in tiny structures that can release their drug load when interacting with enzymes typically found in pancreatic cancer cells. We observed that these micelles showed promising results in laboratory settings, enhancing the effectiveness of paclitaxel against aggressive pancreatic cancer cells compared to using paclitaxel alone.
Moreover, we noted that the vitamin D in the micelles may play a dual role: serving as both a hydrophobic core for drug delivery and a contributor to synergetic therapeutic effects. Our findings suggest that leveraging vitamin D in this way could increase the efficacy of existing treatment options for pancreatic cancer patients, which is particularly significant given the challenges currently faced in treating this disease.
Read More
9
We explored the potential of iodinated copper-cysteamine (Cu-Cy-I) nanoparticles to enhance cancer treatment when combined with X-ray therapy. The study specifically focused on how these nanoparticles could improve the effectiveness of radiotherapy by increasing the generation of reactive oxygen species (ROS) in tumor cells. This increase in ROS leads to more significant DNA damage in cancer cells, making them more susceptible to radiation treatment.
Our findings revealed that when 4T1 tumor cells were treated with Cu-Cy-I nanoparticles alongside X-ray irradiation, there was a notable improvement in tumor cell killing compared to X-ray treatment alone. Additionally, in mouse models with breast carcinoma, the combination treatment led to better tumor growth inhibition and extended survival time for the mice.
However, we acknowledge that the effectiveness of the iodine component in the nanoparticles at lower doses was not verified in this study. The results suggest that Cu-Cy-I nanoparticles have promise as radiosensitizers in cancer therapy, but more research is needed, particularly regarding the synthesis of smaller nanoparticles for further evaluation.
Our findings revealed that when 4T1 tumor cells were treated with Cu-Cy-I nanoparticles alongside X-ray irradiation, there was a notable improvement in tumor cell killing compared to X-ray treatment alone. Additionally, in mouse models with breast carcinoma, the combination treatment led to better tumor growth inhibition and extended survival time for the mice.
However, we acknowledge that the effectiveness of the iodine component in the nanoparticles at lower doses was not verified in this study. The results suggest that Cu-Cy-I nanoparticles have promise as radiosensitizers in cancer therapy, but more research is needed, particularly regarding the synthesis of smaller nanoparticles for further evaluation.
Read More
9
Iodine enhances lung cancer treatment
We conducted a retrospective study focusing on patients with driver gene-negative non-small cell lung cancer (NSCLC) to explore the effectiveness of iodine-125 (I) seed implantation when paired with immune checkpoint inhibitors (ICIs) and chemotherapy (CT). In our analysis of 95 patients, we compared two groups: one treated with I seed implantation alongside ICIs and CT, and the other treated with conventional radiotherapy (RT) with the same additional therapies.
Our primary goal was to assess the median progression-free survival (mPFS), alongside secondary outcomes that included the one- and two-year progression-free survival rates, as well as the occurrence of adverse events related to treatments. The results were promising: patients who received iodine treatment experienced longer survival times and reported fewer adverse effects compared to those undergoing traditional RT.
The findings suggest that Iodine-125 seed implantation could be a more advantageous option for treating this specific type of lung cancer, offering a precision approach that minimizes damage to healthy lung tissue. This less invasive method could provide patients with a better quality of life while still tackling the disease effectively.
Our primary goal was to assess the median progression-free survival (mPFS), alongside secondary outcomes that included the one- and two-year progression-free survival rates, as well as the occurrence of adverse events related to treatments. The results were promising: patients who received iodine treatment experienced longer survival times and reported fewer adverse effects compared to those undergoing traditional RT.
The findings suggest that Iodine-125 seed implantation could be a more advantageous option for treating this specific type of lung cancer, offering a precision approach that minimizes damage to healthy lung tissue. This less invasive method could provide patients with a better quality of life while still tackling the disease effectively.
Read More
9
Iodine treatment aids recurrent cancer
We observed a compelling case where a biodegradable hydrogel spacer was used alongside iodine-125 brachytherapy to treat recurrent prostate cancer. This innovative approach involved placing the spacer to create space between the prostate and the rectum, which significantly reduced radiation exposure to healthy tissues during the treatment.
Following initial external beam radiotherapy in 2015, the patient showed signs of local recurrence by 2022. To address this, the treatment plan included not just the iodine-125 brachytherapy but also the hydrogel spacer, which was placed in January 2024 just before the radiation treatment. Six months later, we noted a remarkable drop in the patient’s prostate-specific antigen (PSA) levels, indicating a positive response to the treatment.
This case showcases the potential benefits of using iodine treatment in combination with advanced techniques like hydrogel spacers. The results suggest that this method not only improves the effectiveness of therapy but also ensures higher safety by protecting adjacent tissues from unnecessary radiation damage. Overall, we find this integration of technology highly beneficial for managing recurrent cancer challenges.
Following initial external beam radiotherapy in 2015, the patient showed signs of local recurrence by 2022. To address this, the treatment plan included not just the iodine-125 brachytherapy but also the hydrogel spacer, which was placed in January 2024 just before the radiation treatment. Six months later, we noted a remarkable drop in the patient’s prostate-specific antigen (PSA) levels, indicating a positive response to the treatment.
This case showcases the potential benefits of using iodine treatment in combination with advanced techniques like hydrogel spacers. The results suggest that this method not only improves the effectiveness of therapy but also ensures higher safety by protecting adjacent tissues from unnecessary radiation damage. Overall, we find this integration of technology highly beneficial for managing recurrent cancer challenges.
Read More
9
Iodine peptides show cancer treatment promise
We explored the effectiveness of iodine-labeled peptides, specifically I-TFMP-Y4 and I-Caerin 1.1, in treating hepatocellular carcinoma, a common type of liver cancer. Our study included in vitro experiments where we assessed how these peptides affected the growth of liver cancer cells, as well as in vivo tests using a hormone-treated nude mouse model.
We found that both I-Caerin 1.1 and I-TFMP-Y4 were effective at inhibiting the proliferation of Hepg2 cells, which are a model for liver cancer. Interestingly, while I-Caerin 1.1 showed a significant impact, we observed that TFMP-Y4 alone did not inhibit the liver cancer cells, suggesting its effectiveness might rely on its pairing with Iodine.
Additionally, we noted that I-TFMP-Y4 has the potential to lessen adverse reactions during treatment compared to I-Caerin 1.1. This finding is particularly important as it may improve the safety profile of the treatment, making it more acceptable for patients undergoing therapy.
We found that both I-Caerin 1.1 and I-TFMP-Y4 were effective at inhibiting the proliferation of Hepg2 cells, which are a model for liver cancer. Interestingly, while I-Caerin 1.1 showed a significant impact, we observed that TFMP-Y4 alone did not inhibit the liver cancer cells, suggesting its effectiveness might rely on its pairing with Iodine.
Additionally, we noted that I-TFMP-Y4 has the potential to lessen adverse reactions during treatment compared to I-Caerin 1.1. This finding is particularly important as it may improve the safety profile of the treatment, making it more acceptable for patients undergoing therapy.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 6 Reviews
7.9
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Aids bone health
I take vitamin D3 constantly; it ensures normal growth and development of bones, preventing rickets and osteoporosis. It regulates mineral metabolism, promotes muscle tone, improves immunity, and is vital for thyroid function and blood clotting. It also helps restore protective sheaths around nerves and regulates blood pressure and heartbeat while inhibiting cancer cell growth. Good company and optimal dosage for winter. You can take it every other day if necessary.
Read More
7.5
Value price
Great combo! This product tests well and has become a staple for us, primarily for the D3 and also for the good amount of natural iodine, essential for metabolism and anti-cancer. Great price, too, and it comes in a blue bottle for an added bonus. We trust this.
Read More
7
Essential for health
Fine! Research data from recent years indicate a pandemic of vitamin D deficiency, and this vitamin is everything! Normal levels of vitamin D protect against cancer, diabetes, depression, etc. It facilitates phosphorus and calcium absorption and acts as an immunomodulator. Its deficiency frequently leads to viral and bacterial infections.
Read More
7
Deficiency concerns
Research data from recent years indicate a pandemic of vitamin D deficiency, and this vitamin is everything! Normal levels of vitamin D protect against cancer, diabetes, depression, etc. It allows for phosphorus and calcium absorption, acting as an immunomodulator, and its deficiency is associated with frequent viral and bacterial infections.
Read More
7.5
High-quality product
Great! This is the highest quality vitamin D alongside iodine. It's easy to take, and the combination helps rebuild protective membranes around nerves, regulates blood pressure, and prevents cancer cell growth. It offers numerous benefits that everyone needs. Of all the supplements, this complex and brand is my favourite for its effect.
Read More
Frequently Asked Questions
7.5
Aids bone health
I take vitamin D3 constantly; it ensures normal growth and development of bones, preventing rickets and osteoporosis. It regulates mineral metabolism, promotes muscle tone, improves immunity, and is vital for thyroid function and blood clotting. It also helps restore protective sheaths around nerves and regulates blood pressure and heartbeat while inhibiting cancer cell growth. Good company and optimal dosage for winter. You can take it every other day if necessary.
7
Essential for health
Fine! Research data from recent years indicate a pandemic of vitamin D deficiency, and this vitamin is everything! Normal levels of vitamin D protect against cancer, diabetes, depression, etc. It facilitates phosphorus and calcium absorption and acts as an immunomodulator. Its deficiency frequently leads to viral and bacterial infections.
7
Deficiency concerns
Research data from recent years indicate a pandemic of vitamin D deficiency, and this vitamin is everything! Normal levels of vitamin D protect against cancer, diabetes, depression, etc. It allows for phosphorus and calcium absorption, acting as an immunomodulator, and its deficiency is associated with frequent viral and bacterial infections.
7.5
High-quality product
Great! This is the highest quality vitamin D alongside iodine. It's easy to take, and the combination helps rebuild protective membranes around nerves, regulates blood pressure, and prevents cancer cell growth. It offers numerous benefits that everyone needs. Of all the supplements, this complex and brand is my favourite for its effect.
7.5
Value price
Great combo! This product tests well and has become a staple for us, primarily for the D3 and also for the good amount of natural iodine, essential for metabolism and anti-cancer. Great price, too, and it comes in a blue bottle for an added bonus. We trust this.
8
We explored the potential benefits of a vitamin D analog in treating prostate cancer, which is a major cause of cancer-related deaths among men. Our work focused on understanding how this vitamin D form impacts cancer resistance and the tumor microenvironment. We used the Pten mouse model to observe the therapeutic effects of the vitamin D analog.
One significant finding was that combining this vitamin D analog with the chemotherapy drug docetaxel could overcome resistance seen in some prostate cancer cases. This combination showed promising results in primary cancer spheroids and xenografts from a patient whose cancer had resisted both docetaxel and androgen deprivation therapy.
These insights suggest that vitamin D analogs might offer new and effective strategies for managing advanced prostate cancer, particularly for those patients who have not responded well to standard treatments.
One significant finding was that combining this vitamin D analog with the chemotherapy drug docetaxel could overcome resistance seen in some prostate cancer cases. This combination showed promising results in primary cancer spheroids and xenografts from a patient whose cancer had resisted both docetaxel and androgen deprivation therapy.
These insights suggest that vitamin D analogs might offer new and effective strategies for managing advanced prostate cancer, particularly for those patients who have not responded well to standard treatments.
5
We conducted an observational study to examine the levels of vitamin D in female patients with benign and malignant breast diseases. The research aimed to determine if there is a significant difference in vitamin D levels between those with non-cancerous conditions and those diagnosed with breast cancer.
During the study, we analyzed adult female patients admitted to a surgical department. Importantly, we excluded those who had taken vitamin D supplements recently or who had prior vitamin D deficiencies. By measuring serum vitamin D levels through a specific testing method, we were able to gather meaningful data about their relationship to breast health.
Our findings indicated a notable difference in average vitamin D levels when comparing the two groups. This suggests that inadequate vitamin D could be linked to an increased risk of developing breast cancer. Therefore, we explored the potential benefits of vitamin D supplementation as a preventive measure against breast cancer—though we acknowledge that larger and more controlled studies are essential to draw firm conclusions.
At the same time, we recognize that vitamin D has effects beyond bone health, and it is crucial to consider these broader impacts when discussing its role in cancer risk.
During the study, we analyzed adult female patients admitted to a surgical department. Importantly, we excluded those who had taken vitamin D supplements recently or who had prior vitamin D deficiencies. By measuring serum vitamin D levels through a specific testing method, we were able to gather meaningful data about their relationship to breast health.
Our findings indicated a notable difference in average vitamin D levels when comparing the two groups. This suggests that inadequate vitamin D could be linked to an increased risk of developing breast cancer. Therefore, we explored the potential benefits of vitamin D supplementation as a preventive measure against breast cancer—though we acknowledge that larger and more controlled studies are essential to draw firm conclusions.
At the same time, we recognize that vitamin D has effects beyond bone health, and it is crucial to consider these broader impacts when discussing its role in cancer risk.
9
We explored the potential of vitamin D-based micelles designed to deliver paclitaxel, a key chemotherapy drug, specifically for pancreatic cancer treatment. This study focuses on developing enzyme-responsive micelles that not only carry paclitaxel but also utilize vitamin D as an integral part of the delivery system.
The micelles are made by combining vitamin D with polyethylene glycol, resulting in tiny structures that can release their drug load when interacting with enzymes typically found in pancreatic cancer cells. We observed that these micelles showed promising results in laboratory settings, enhancing the effectiveness of paclitaxel against aggressive pancreatic cancer cells compared to using paclitaxel alone.
Moreover, we noted that the vitamin D in the micelles may play a dual role: serving as both a hydrophobic core for drug delivery and a contributor to synergetic therapeutic effects. Our findings suggest that leveraging vitamin D in this way could increase the efficacy of existing treatment options for pancreatic cancer patients, which is particularly significant given the challenges currently faced in treating this disease.
The micelles are made by combining vitamin D with polyethylene glycol, resulting in tiny structures that can release their drug load when interacting with enzymes typically found in pancreatic cancer cells. We observed that these micelles showed promising results in laboratory settings, enhancing the effectiveness of paclitaxel against aggressive pancreatic cancer cells compared to using paclitaxel alone.
Moreover, we noted that the vitamin D in the micelles may play a dual role: serving as both a hydrophobic core for drug delivery and a contributor to synergetic therapeutic effects. Our findings suggest that leveraging vitamin D in this way could increase the efficacy of existing treatment options for pancreatic cancer patients, which is particularly significant given the challenges currently faced in treating this disease.
References
- Len-Tayon K, Metzger D, Laverny G. [New insights of vitamin D-based therapy for prostate cancer]. Med Sci (Paris). 2025;41:154. doi:10.1051/medsci/2025011
- Soni D, Tiwari A, Kushwah PS, Dubey S, Khan S. Levels of Serum 25-Hydroxy Vitamin D in Benign and Malignant Breast Disease Patients: An Observational Study. Cureus. 2025;17:e78283. doi:10.7759/cureus.78283
- Peixoto D, Ravasco JM, Blanco-Fernandez B, Veiga F, Concheiro A, et al. Enzyme-responsive vitamin D-based micelles for paclitaxel-controlled delivery and synergistic pancreatic cancer therapy. Mater Today Bio. 2025;31:101555. doi:10.1016/j.mtbio.2025.101555
- Kuhlen M, Kunstreich M, Eilsberger F, Luster M, Redlich A. Pediatric differentiated thyroid carcinoma leading to fatal lung fibrosis. Eur Thyroid J. 2025;14. doi:10.1530/ETJ-24-0341
- Wang Y, Huang S, Huang R. Two or three weeks of thyroid hormone withdrawal before initial I therapy for patients with differentiated thyroid carcinoma?. BMC Cancer. 2025;25:370. doi:10.1186/s12885-024-13313-3
- Shan C, Xu S, Cai G, Li M, Wang T, et al. Clinical outcome and prognosis of differentiated thyroid carcinoma with distant metastasis. Nucl Med Commun. 2025. doi:10.1097/MNM.0000000000001965
- Zhang M, Yang Y, Xu Y, Wang J, Li S. Iodinated Copper-Cysteamine Nanoparticles as Radiosensitizers for Tumor Radiotherapy. Pharmaceutics. 2025;17. doi:10.3390/pharmaceutics17020149
- Ttofi E, Kyriacou C, Leontiou T, Parpottas Y. A Method for Calculating Small Sizes of Volumes in Postsurgical Thyroid SPECT/CT Imaging. Life (Basel). 2025;15. doi:10.3390/life15020200
- Nappi C, Megna R, Zampella E, Volpe F, Piscopo L, et al. External validation of a predictive model for post-treatment persistent disease by I whole-body scintigraphy in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2025. doi:10.1007/s00259-025-07124-2
- Condello V, Marchettini C, Ihre-Lundgren C, Nilsson JN, Juhlin CC. Comprehensive Gene Expression Analysis in Papillary Thyroid Carcinoma Reveals a Transcriptional Profile Associated with Reduced Radioiodine Avidity. Endocr Pathol. 2025;36:4. doi:10.1007/s12022-025-09849-0
- Cao J, Li X, Liang H, Li Y, Zhao F, et al. The efficacy analysis of radioactive iodine therapy for familial non-medullary thyroid cancer in the era of personalized medicine: a cohort study and a meta-analysis. Ann Nucl Med. 2025. doi:10.1007/s12149-025-02029-4
- Tao X, Liang L, Xu J, Xie L, Wen Q, et al. Efficacy and safety of immune checkpoint inhibitors combined with iodine-125 seed implantation in driver gene-negative non-small cell lung cancer: a retrospective cohort study. J Thorac Dis. 2025;17:278. doi:10.21037/jtd-24-1403
- Bayoumi NA, El-Shershaby HM, Darwish WM. Synthesis of iron oxide nanocrystals functionalized with hyaluronic acid and I-cetuximab for targeted combined (radio-photothermal) treatment of HepG2 cells. Int J Biol Macromol. 2025;305:140890. doi:10.1016/j.ijbiomac.2025.140890
- McGoron AJ, Garcia JM, Uluvar B, Gulec SA. Thyroid differentiation profile for differentiated thyroid cancer. Endocr Oncol. 2025;5:e240072. doi:10.1530/EO-24-0072
- Yang LG, Yang ZG, Zhang J, Fu YL. Effects of I and TSH suppression therapy on METTL3, METTL14 levels and recurrence in thyroid cancer. Am J Cancer Res. 2025;15:42. doi:10.62347/THJB4749
- Lazrek A, Finocchi Ghersi S, Petre A, Houabes S, Serre AA, et al. Case report of the first use of a hydrogel rectal spacer for prostate cancer reirradiation via LDR brachytherapy: applications and technical notes. Front Oncol. 2025;15:1494304. doi:10.3389/fonc.2025.1494304
- Adnan Z, Sabo E, Kassem S. Metastatic papillary thyroid carcinoma with internal jugular vein tumor thrombus - A case report and review of the literature. Front Endocrinol (Lausanne). 2025;16:1505800. doi:10.3389/fendo.2025.1505800
- Ding T, Ge X, Hao S, Wang Z, Zhang W, et al. Nomogram prediction model for overall survival of late-stage lung cancer patients undergoing iodine-125 particle implantation brachytherapy. J Contemp Brachytherapy. 2024;16:410. doi:10.5114/jcb.2024.146836
- Du J, Ren W, Liu W, Zhou Y, Li Y, et al. Experimental study of iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in the treatment of hepatocellular carcinoma with internal irradiation. BMC Cancer. 2025;25:245. doi:10.1186/s12885-025-13666-3
